Inflammatory bowel disease (IBD) is a chronic disease of the gastrointestinal tract, thought to be due to an abnormal response of the body's immune system. According to The Centers for Disease Control and Prevention (CDC), more than three million people in the U.S. are affected by IBD. The two most common types of IBD are Crohn's disease and ulcerative colitis.
Supplements can play an important role in helping people manage their IBD. These can range from probiotics, to teas, to different herbal compounds, a large number of possibilities make it hard to know what works.
Dr. Shekhar Challa, gastroenterologist from Kansas Medical Center and Dr. Chethan Sarabu, Director of Clinical Informatics at doc.ai and physician at Stanford Medicine are in the process of analyzing the data from the IBD Digital Health Trial, participants holistically and will share the results in the coming months once published.
The doc.ai digital health trial on Crohn’s disease that was conducted in 2019 will use artificial intelligence to predict the optimal food supplements for patients with inflammatory bowel disease based on their phenome (physical characteristics), physiome (activity), exposome (location) along with their tracked symptoms and supplements. By applying artificial intelligence (A.I.) technology to this data, there is a chance to identify common patterns and gain deeper insights on the disease.
Our digital health trial is the first framework for establishing how A.I. can help predict which supplements may be optimal for people suffering with inflammatory bowel disease, a chronic condition with no easy answers.
Stay tuned for an update on this trial when the research paper is published later this year. If you have questions, email doc.ai at email@example.com.